Furthermore, cisplatin has been shown to increase chemoresistance in lung cancer cells by upregulating PD-L1 and inhibiting the tumor-infiltrating lymphocytes through the activation of phosphatidylinositol 3-kinase/protein kinase B pathway [170]. Here, CD274 is linked to lung cancer.